HeXun Biosciences Co (ROCO:6986) Tax Expense: NT$4.5 Mil (TTM As of Dec. 2025)


ROCO:6986 HeXun Biosciences Co Ltd ROCO:6986
23 GF Score
Price NT$47.00
! 1 Warning Sign
View Full Analysis

What is HeXun Biosciences Co Tax Expense?

HeXun Biosciences Co ROCO:6986 23 Tax Expense is NT$4.5 Mil as of Dec. 2025. GuruFocus rates ROCO:6986 with a GF Score™ of 23/100. The stock has 1 warning sign investors should review.

HeXun Biosciences Co's tax expense for the months ended in Dec. 2025 was NT$2.7 Mil. Its tax expense for the trailing twelve months (TTM) ended in Dec. 2025 was NT$4.5 Mil.


HeXun Biosciences Co  (ROCO:6986) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


HeXun Biosciences Co Tax Expense Related Terms


HeXun Biosciences Co Tax Expense Historical Data

* Premium members only.

The historical data trend for HeXun Biosciences Co's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HeXun Biosciences Co Tax Expense Chart

HeXun Biosciences Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Tax Expense
Get a 7-Day Free Trial 0.00 0.00 0.00 14.25 14.02

HeXun Biosciences Co Quarterly Data
Dec20 Dec21 Dec22 Jun23 Dec23 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 6.53 7.72 0.00 1.81 2.69
ROCO:6986
23GF Score
HeXun Biosciences Co Ltd ROCO:6986
Tax Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HeXun Biosciences Co Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$4.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Expense →
What does a Tax Expense of NT$4.5 Mil mean?
HeXun Biosciences Co (ROCO:6986) has a Tax Expense of NT$4.5 Mil as of Dec. 2025. Tax expense is the amount of tax the company pays in an accounting period. View historical data on HeXun Biosciences Co and its competitors.
Is HeXun Biosciences Co's Tax Expense too high?
HeXun Biosciences Co's current Tax Expense is NT$4.5 Mil. Overall, HeXun Biosciences Co has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does HeXun Biosciences Co's Tax Expense compare to VRTX and REGN?
HeXun Biosciences Co's Tax Expense of NT$4.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Expense for a Biotechnology company?
A good Tax Expense depends on the Biotechnology industry context. However, Tax Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Expense mean?
A high Tax Expense can signal that a stock is expensive relative to its fundamentals. Tax expense is the amount of tax the company pays in an accounting period. View historical data on HeXun Biosciences Co and its competitors. HeXun Biosciences Co's current Tax Expense is NT$4.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HeXun Biosciences Co stock overvalued right now?
HeXun Biosciences Co (ROCO:6986) has a current Tax Expense of NT$4.5 Mil. The current Tax Expense is NT$4.5 Mil. HeXun Biosciences Co's overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Expense calculated?
Tax Expense is calculated from a company's financial statements. For HeXun Biosciences Co (ROCO:6986), the current Tax Expense is NT$4.5 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

HeXun Biosciences Co Business Description

Address Chunri Road, 6 F., No. 1490, Taoyuan District, Taoyuan, TWN
HeXun Biosciences Co Ltd is engaged in the research and development of cell drugs and cell derivatives. It conducts research and development jointly with medical research institutions to use stem cells to treat cardiovascular, immune-inflammatory, and neurodegenerative diseases to develop innovative cell drugs and treatment methods. The company's main business items are new drug research and development, biotechnology services, and research and development services, such as: commissioned research and development and production services for cell medicine, agency testing and development services, and biomedical consulting services, etc.
23GF Score

Get the complete analysis for ROCO:6986

Tax Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$47.00
Price